Drawing for IOMX

USPTO serial 87802718

IOMX

Reviewed by CopyMark Law Group

Reg. 6236118Status 700Renewal
Filing date
Status date
Registration date
Jan 5, 2021
Examiner
WATTS-FITZGERALD,CAITLIN C
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with IOMX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*

Plus Government fees of $975

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Allison R. Imber

Allison R. Imber Allen, Dyer, Doppelt & Gilchrist, P.A.255 S. Orange Avenue, Suite 1401Orlando, FL 32801United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals, medical and veterinary preparations, pharmaceutical preparations and formulations, and medicated health preparations, all of the aforesaid goods for use in the treatment or prevention of human and animal diseases, disorders and conditions, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, disorders and conditions, and for use in the treatment or prevention of complications associated with such diseases, disorders and conditions; Pharmaceuticals, medical and veterinary preparations, pharmaceutical preparations and formulations, and medicated health preparations, all of the aforesaid goods for use in the treatment or prevention of human and animal diseases, disorders and conditions, namely, bone sensory, viral, urinary, renal, metabolic or central nervous system diseases, disorders and conditions, and for use in the treatment or prevention of complications associated with such diseases, disorders and conditions; Pharmaceuticals, medical and veterinary preparations, pharmaceutical preparations and formulations, and medicated health preparations, all of the aforesaid goods for use in the treatment or prevention of human and animal diseases, disorders and conditions, namely, infectious, auto-immune or immune-related, cell-proliferative or oncologic diseases, disorders and conditions, cancers, tumours and metastases, and for use in the treatment or prevention of complications associated with such diseases, disorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, bone sensory, viral, urinary, renal, metabolic or central nervous system diseases, disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, infectious, auto-immune or immune-related, cell-proliferative or oncologic diseases, disorders and conditions, cancers, tumours and metastases, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditionsACTIVE—
010Diagnostic apparatus for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions, specifically, sample-analysis devices and related data-analysis software sold as a unit, nucleic acid-analysis or protein-analysis diagnosis apparatus, and diagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit; Diagnostic apparatus for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, bone sensory, viral, urinary, renal, metabolic or central nervous system diseases disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions, specifically, sample-analysis devices and related data-analysis software sold as a unit, nucleic acid-analysis or protein-analysis diagnosis apparatus, and diagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit; Diagnostic apparatus for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, infectious, auto-immune or immune-related, cell-proliferative or oncologic diseases, disorders and conditions, cancers, tumours and metastases, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions, specifically, sample-analysis devices and related data-analysis software sold as a unit, nucleic acid-analysis or protein-analysis diagnosis apparatus, and diagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unitACTIVE—
042Scientific services, namely, scientific research, analysis and testing in the fields of biology, chemistry or medicine, as well as in the fields of immunology, oncology, molecular biology, cellular biology, biochemistry and medicinal chemistry; Scientific services, namely, scientific research, analysis and testing in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents, and diagnostic apparatus; Design and development of computer software for database management, cloud-storage of data, data-management, data-query, data-analysis and data-presentation, for the query, analysis and presentation of the sequence or structure of molecules, or for predicting or providing a medical diagnosis or prognosis, as well as for controlling and managing patient medical information, with any of the aforementioned services for use in the fields of biology, chemistry or medicine, as well as for use in the fields of immunology, oncology, molecular biology, cellular biology, biochemistry and medicinal chemistry; Design and development of computer software for database management, cloud-storage of data, data-management, data-query, data-analysis and data-presentation, as well as for the query, analysis and presentation of the sequence or structure of molecules, or for predicting or providing a medical diagnosis or prognosis, with any of the aforementioned services for use in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents, and diagnostic apparatusACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 5, 2026REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Feb 8, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 8, 2024ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Feb 8, 2024EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Feb 8, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 8, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 8, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Feb 8, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 6, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Mar 6, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 6, 2023ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Mar 6, 2023EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Mar 6, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 6, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 6, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Oct 8, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 8, 2021EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Oct 8, 2021EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Oct 8, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 8, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 5, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 20, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 20, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 30, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 15, 2020FIXDELECTRONIC RECORD REVIEW COMPLETE—
Sep 11, 2020ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Sep 10, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 25, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 24, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 24, 2020ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Jul 9, 2020GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jul 9, 2020GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 9, 2020CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 24, 2020RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Dec 18, 2019RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jun 18, 2019RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Dec 12, 2018GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Dec 12, 2018GNSLLETTER OF SUSPENSION E-MAILED—
Dec 12, 2018CNSLSUSPENSION LETTER WRITTEN—
Dec 10, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 10, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 3, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 4, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 4, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 4, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 4, 2018DOCKASSIGNED TO EXAMINER—
Apr 3, 2018AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Mar 30, 2018ALIEASSIGNED TO LIE—
Mar 16, 2018PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Feb 26, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 22, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance